Extensive research on cell encapsulation strategies has enabled the development of a variety of technologies capable of immobilizing / enclosing therapeutic entities within biocompatible matrices / carriers. Such products offer a myriad of advantages, and have demonstrated the capability to address existing challenges related to cell therapies and certain other types of interventions as well.
To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this link
The USD 3.7 billion (by 2030) financial opportunity within the encapsulated cell therapies and encapsulation technologies market has been analyzed across the following segments:
- Type of licensing deal payment
- Upfront payment
- Milestone payment
- Therapeutic area
- Metabolic disorder
- Neurological disorder
- Ophthalmic disorder
- Oncological disorder
- Target disease indication
- Ataxia telangiectasia
- Breast cancer
- Diabetes
- Glaucoma
- Head and neck cancer
- Macular telangectasia
- Pancreatic cancer
- Parkinson's disease
- Retinitis pigmentosa
- Type of encapsulation material used
- Alginate-based microcapsule
- Cellulose hydrogel
- Medical-grade plastic
- Red blood cell
- Key geographical region
- North America
- Europe
- Asia-Pacific and rest of the world
The Cell Encapsulation: Focus on Therapeutics and Technologies, 2019-2030 report features the following companies, which we identified to be key players in this domain:
- ALTuCELL
- Azellon Cell Therapeutics
- Beta-Cell
- Betalin Therapeutics
- CellProtect Biotechnology
- Diatranz Otsuka
- Encellin
- EryDel
- Gloriana Therapeutics
- Living Cell Technologies
- MaxiVAX
- Neurotech Pharmaceuticals
- PharmaCyte Biotech
- Semma Therapeutics
- Sernova
Table of Contents
- Preface
Executive Summary
- Introduction
- Current Market Landscape
- Encapsulated Cell Therapies and Encapsulation Technologies for Metabolic Disorders: Company Profiles
- Encapsulated Cell Therapies and Encapsulation Technologies for Non-Metabolic Disorders: Company Profiles
- Patent Analysis
- Clinical Trial Analysis
- Recent Partnerships
- Funding and Investment Analysis
- Grant Analysis
- Potential Strategic Partners
- Market Forecast
- Conclusion
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
[email protected]
Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery / Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to its list of offerings.
Presently, in silico tools / approaches are available for the identification, selection and optimization of pharmacological leads.
in fact, the predictive power of such solutions has been demonstrated to enable researchers to bypass the traditional experimental screening of billions of molecules against hundreds of biological targets, thereby, allowing significant reductions in the investment of both time and resources.
It is worth mentioning that about 30% of players presently offer end-to-end drug discovery services Over 150 software solutions are currently available for use in drug discovery Around 90 companies are currently providing software tools, web applications and other technology platforms for drug discovery.
Examples of popular softwares include (in alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space Navigator, SaaS Platform and VolSurf+.
Around 40% of the companies claim to specialize in antibodies, proteins and peptidesWithin the antibodies segment, nearly 60% of in silico service offerings are focused on the discovery of monoclonal antibodies.
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
